Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2018

  • ID: 4531952
  • Report
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BioLingus AG
  • Eurofins Advinus Ltd
  • iCo Therapeutics Inc.
  • ManRos Therapeutics
  • Nanomerics Ltd
  • Oblita Therapeutics BVBA
  • MORE
Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2018, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights:

This latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 16, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 16 and 12 molecules, respectively.

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BioLingus AG
  • Eurofins Advinus Ltd
  • iCo Therapeutics Inc.
  • ManRos Therapeutics
  • Nanomerics Ltd
  • Oblita Therapeutics BVBA
  • MORE
Introduction

Leishmaniasis (Kala-Azar) - Overview

Leishmaniasis (Kala-Azar) - Therapeutics Development

Leishmaniasis (Kala-Azar) - Therapeutics Assessment

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development

Leishmaniasis (Kala-Azar) - Drug Profiles

Leishmaniasis (Kala-Azar) - Dormant Projects

Leishmaniasis (Kala-Azar) - Discontinued Products

Leishmaniasis (Kala-Azar) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Cerenis Therapeutics Holding SA, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Eurofins Advinus Ltd, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by GlaxoSmithKline Plc, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SL, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Molecular Targeting Technologies Inc, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Pfizer Inc, H1 2018

Leishmaniasis (Kala-Azar) - Pipeline by Sequella Inc, H1 2018

Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2018

Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioLingus AG
  • Cerenis Therapeutics Holding SA
  • Daiichi Sankyo Co Ltd
  • Eurofins Advinus Ltd
  • GlaxoSmithKline Plc
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Matinas BioPharma Holdings Inc
  • Molecular Targeting Technologies Inc
  • Mologen AG
  • Nanomerics Ltd
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Pfizer Inc
  • Sequella Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll